Role of Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in the Pathophysiology of Ischemic Stroke in Human and Albino Rats
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Alpha-synuclein levels
研究概览
简要总结
This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:
- Is there an association between iron and alpha-synuclein accumulation in ischemic stroke?
- Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 50 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients at the age between 50-70 years.
- •Patients having neurological symptoms of acute ischemic stroke.
排除标准
- •Patients with acute hemorrhagic stroke.
- •Patients with Parkinson's disease (PD).
- •Patients with dementia, and Alzheimer's disease.
- •Patients with any type of malignancy.
- •Patients with central nervous system infection.
研究组 & 干预措施
Control
24 healthy age and sex-matched controls
干预措施: Serum Iron (Diagnostic Test)
Control
24 healthy age and sex-matched controls
干预措施: RBCs Alpha-synuclein (Diagnostic Test)
Control
24 healthy age and sex-matched controls
干预措施: Serum Soluble lymphocyte activation gene (Diagnostic Test)
Control
24 healthy age and sex-matched controls
干预措施: Brain computed tomography (Radiation)
Patients with acute Ischemic stroke
24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.
Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded.
干预措施: Serum Iron (Diagnostic Test)
Patients with acute Ischemic stroke
24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.
Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded.
干预措施: RBCs Alpha-synuclein (Diagnostic Test)
Patients with acute Ischemic stroke
24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.
Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded.
干预措施: Serum Soluble lymphocyte activation gene (Diagnostic Test)
Patients with acute Ischemic stroke
24 patients between 50-70 years having neurological symptoms of acute ischemic stroke will be included.
Patients with acute hemorrhagic stroke, Parkinson's disease, dementia, Alzheimer's disease, malignancy, and central nervous system infection will be excluded.
干预措施: Brain computed tomography (Radiation)
Control rats
8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.
干预措施: Brain Iron (Diagnostic Test)
Control rats
8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.
干预措施: Brain Alpha-synuclein (Diagnostic Test)
Control rats
8 rats will be subjected to a Sham operation and will be injected intramuscularly immediately after the operation with an equivalent 0.9% saline solution. After 24 hours they will be sacrificed.
干预措施: Brain lymphocyte activation gene (Diagnostic Test)
Rats with ischemic stroke
8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.
干预措施: Brain Iron (Diagnostic Test)
Rats with ischemic stroke
8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.
干预措施: Brain Alpha-synuclein (Diagnostic Test)
Rats with ischemic stroke
8 rats will be subjected to bilateral common carotid artery occlusion (CCAO) for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with an equivalent 0.9% saline solution. They will be sacrificed after 24 hours of reperfusion.
干预措施: Brain lymphocyte activation gene (Diagnostic Test)
Rats with ischemic stroke + deferoxamine
8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
干预措施: Brain Iron (Diagnostic Test)
Rats with ischemic stroke + deferoxamine
8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
干预措施: Brain Alpha-synuclein (Diagnostic Test)
Rats with ischemic stroke + deferoxamine
8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
干预措施: Brain lymphocyte activation gene (Diagnostic Test)
Rats with ischemic stroke + deferoxamine
8 rats will be subjected to bilateral CCAO for 30 minutes and will be injected intramuscularly immediately after removing the occlusion with deferoxamine (200 mg/kg), They will be sacrificed after 24 hours of reperfusion.
干预措施: Deferoxamine (Drug)
结局指标
主要结局
Alpha-synuclein levels
时间窗: 6 months
Alpha-synuclein levels in RBCs in ischemic patients and control
Levels of Soluble lymphocyte activation gene-3
时间窗: 6 months
Serum soluble lymphocyte activation gene-3 in ischemic patients and control
levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size
时间窗: 6 months
stroke severity will be evaluated by the National Institutes of Health Stroke Scale (NIHSS) and size of infarction will be detected by brain CT
Iron levels in brain of rats
时间窗: 2 months
Iron levels in brain homogenate of rats in the three rat groups
Levels of Alpha-synuclein expression in brain of rats
时间窗: 2 months
Alpha-synuclein expression in brain of rats in different groups
Iron levels
时间窗: 6 months
Serum iron levels in ischemic patients and control
Levels of Lymphocyte activation gene-3 expression in brain of rats
时间窗: 2 months
lymphocyte activation gene-3 expression in brain of rats in different groups
次要结局
未报告次要终点
研究者
Asmaa Abdel-mageed Muhammed
Lecturer
Aswan University Hospital